• The document is a transcript of the Q2 & H1 FY27 Earnings Conference Call held on November 16, 2026, to discuss the financial results for the second quarter and half year ended September 30, 2026.
  • The event was an earnings call hosted by Systematix Group. Management participants included Mr. S.C. Mehta (Chairman and Managing Director), Mr. Subhash Anand (President and Chief Financial Officer), Mr. Tarun Sinha (President – Technical Ammonium Nitrate), and Mr. Suparas Jain (Executive Vice President – Corporate Finance).
  • The transcript was submitted to the stock exchanges pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015. It is also made available on the company's website at https://www.dfpcl.com/.
  • The call included a disclaimer that certain statements could be forward-looking in nature, as included in the investor presentation on the stock exchange website.
  • Financial Highlights Discussed:
  • Q2 FY27 Consolidated Revenue: ₹3,334 crores (up 11% YoY)
  • Q2 FY27 EBITDA: ₹750 crores (up 62% YoY)
  • Q2 FY27 EBITDA Margin: 22.5% (vs. 15.5% YoY)
  • Q2 FY27 PAT: ₹394 crores (up 84% YoY)
  • H1 FY27 Consolidated Revenue: ₹6,590 crores (up 16% YoY)
  • H1 FY27 Operating EBITDA: ₹1,595 crores (up 63% YoY)
  • H1 FY27 PAT: ₹884 crores (up 93% YoY)
  • Net Debt: ₹4,743 crores
  • Net Debt-to-EBITDA: 1.5x
  • H1 Capex: ₹774 crores
  • Business Segment Updates:
  • Mining Chemicals: Delivered a good quarter. Volumes moderated due to monsoon disruptions, but improved realizations supported growth. B2C business contributed 16% of segment revenue (vs. 14% a year ago). H2 is typically stronger as mining activity picks up post-monsoon.
  • Industrial Chemicals: Mixed operating environment. Nitric acid volume grew 14% YoY. IPA volume was 17 KT with sequential improvement. Realizations remained strong for IPA, supported by favorable mix and higher pharma grade sales.
  • Crop Nutrition: Challenging quarter due to uneven rainfall, raw material inflation, and high channel inventory. Differentiated offerings (Croptek and specialty fertilizers) contributed 28% of segment revenue. Recent government subsidy announcement provides support. Expects resilient performance in H2 with focus on irrigated markets.
  • Project Updates:
  • Dahej nitric acid project and Gopalpur TAN project are approximately 98% complete.
  • Both projects are expected to commence operations in Q4 FY27 and remain within approved Capex budget.
  • Dahej will add ~300,000 tons of nitric acid capacity (more than doubling current sales of ~240,000-250,000 tons).
  • Gopalpur will add ~380,000 tons of TAN capacity (~60-70% increase from current sales of ~550,000-560,000 tons).
  • Expected utilization: Ramp-up to 75% quickly after commissioning, then to 85%, and crossing 95% in the following year.
  • Strategic Highlights:
  • Performance validated three fundamental strategies: integrated value chain (LNG to ammonia to downstream), alignment with India growth story (mining, infrastructure, manufacturing, agriculture), and shift from commodity to differentiated products and customer solutions.
  • Acquisition of Chardham Chemicals is a strategic step in building downstream capability in mining solutions (commercial production expected in H2 FY28).
  • Company is approaching the end of a major investment cycle, expecting operating cash flow growth to outpace capital deployment.
  • Outlook:
  • Mining chemicals: Healthy underlying demand fundamentals should support realization margins in H2.
  • Industrial chemicals: Seeing early recovery in nitric acid pricing; IPA prices supported by supply tightness.
  • Crop nutrition: Near-term headwinds from El Niño, raw material inflation, and high inventory; positioned for resilient H2 performance.

Additional Notes Section

  • The document is a transcript of the earnings conference call enclosed with the regulatory filing. No separate attachments were mentioned in the provided text.
  • The announcement itself does not contain financial data; the financial figures were discussed during the call and are part of the transcript.
  • The company did not explicitly state that no unpublished price sensitive information (UPSI) would be shared in this specific transcript, but the call was a formal earnings discussion following results announcement.